Conflicts of interest: None.
The use of botulinum toxin-A in the management of neck and anterior chest wall flushing: pilot study
Article first published online: 22 AUG 2013
© 2013 The International Society of Dermatology
International Journal of Dermatology
Volume 52, Issue 12, pages 1547–1550, December 2013
How to Cite
Geddoa, E., Matar, H. E. and Paes, T. R. F. (2013), The use of botulinum toxin-A in the management of neck and anterior chest wall flushing: pilot study. International Journal of Dermatology, 52: 1547–1550. doi: 10.1111/ijd.12200
Funding: Botulinum Toxin-A injections (Botox®) were provided by Allergan Company. No grants or other funds were provided.
- Issue published online: 21 NOV 2013
- Article first published online: 22 AUG 2013
Idiopathic neck and chest wall flushing could cause disabling effects on patients' quality of life. We aimed to evaluate the effectiveness of botulinum toxin-A (BTA) in the management of idiopathic neck and chest wall flushing. This was a pilot prospective clinical study of patients with severe idiopathic neck and anterior chest wall flushing. Two mouse units of BTA were injected intracutaneously with a maximum dose of 100 units per patient per session. The dermatology life quality index is used as the primary outcome measure. Twenty-two patients were included in the study (18 women, four men) with an average age of 26 years (range 18–48). Twenty patients (90.9%) had immediate improvement with almost complete resolution of their flushing. At four weeks follow-up, 18 of 22 patients were included in the final analysis, significant improvement in quality of life was achieved, and mean baseline dermatology life quality index score 7.78 (SD 3.25) improved significantly to 4.23 (SD 3.44) with a mean difference of 3.56 (SD 4.6; 95%, confidence interval 1.27, 5.84) with paired samples t-test 3.29 (d.f. 17) P < 0.004. BTA may provide an effective treatment in the management of idiopathic neck and chest wall flushing.